These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25042683)

  • 1. Meropenem in children receiving continuous renal replacement therapy: clinical trial simulations using realistic covariates.
    Nehus EJ; Mouksassi S; Vinks AA; Goldstein S
    J Clin Pharmacol; 2014 Dec; 54(12):1421-8. PubMed ID: 25042683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
    Nehus EJ; Mizuno T; Cox S; Goldstein SL; Vinks AA
    J Clin Pharmacol; 2016 Mar; 56(3):291-7. PubMed ID: 26222329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
    Kuti JL; Nicolau DP
    Chemotherapy; 2005 Jul; 51(4):211-6. PubMed ID: 15985760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
    Jamal JA; Udy AA; Lipman J; Roberts JA
    Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
    Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
    Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
    Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.
    Hayakawa M; Ito Y; Fujita I; Iseki K; Gando S
    ASAIO J; 2006; 52(4):398-403. PubMed ID: 16883119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
    Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
    Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry.
    Sutherland SM; Zappitelli M; Alexander SR; Chua AN; Brophy PD; Bunchman TE; Hackbarth R; Somers MJ; Baum M; Symons JM; Flores FX; Benfield M; Askenazi D; Chand D; Fortenberry JD; Mahan JD; McBryde K; Blowey D; Goldstein SL
    Am J Kidney Dis; 2010 Feb; 55(2):316-25. PubMed ID: 20042260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
    Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
    J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
    Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
    Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic Dosing in Continuous Renal Replacement Therapy.
    Shaw AR; Mueller BA
    Adv Chronic Kidney Dis; 2017 Jul; 24(4):219-227. PubMed ID: 28778361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.